EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future

Enzo Emanuele iD, Piercarlo Minoretti iD

The FASEB Journal · 2026

DOI: 10.1096/fj.202601680rr ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, 2026. Verfasst von Enzo Emanuele und 1 weiteren Autor:innen. Beteiligte Einrichtung: 2E Science, Robbio, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Clinical Trials as Topic. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although Alzheimer's disease (AD) carries the highest clinical trial failure rate of any major therapeutic area, the strategic lessons from more than two decades of negative outcomes remain insufficiently integrated into drug development practice. To date, trial failures have been examined largely in isolation, with limited attention to the recurring patterns that may connect them across therapeutic classes and disease stages. In this perspective, we propose a taxonomy that assigns AD therapeutic failures to five categories according to the primary driver of each negative outcome—namely wrong target, wrong timing, wrong patient, insufficient target engagement, and wrong endpoint. We subsequently applied this framework to a representative set of drugs that entered clinical testing between 2000 and 2025, comprising anti‐amyloid monoclonal antibodies, β‐site amyloid precursor protein‐cleaving enzyme 1 inhibitors, tau‐directed immunotherapies, neuroimmune‐targeting agents, and metabolic repurposing candidates. Analysis across classes showed that the distribution of failure categories shifted progressively over time, from predominantly target‐related failures in the mid‐to‐late 2010s toward patient‐selection and endpoint‐related failures in the current decade. From these patterns, we formulated strategic recommendations for next‐generation trial design—including biomarker‐driven patient enrichment, mechanism‐specific endpoint validation, and adaptive platform architectures. Because numerous failures examined here replicate the negative outcomes of earlier programs, we conclude that a substantial proportion of late‐stage AD trial failures may be structurally predictable and, through systematic classification, at least in part preventable. Despite these promising findings, the proposed taxonomy should be considered a working heuristic requiring external calibration before prospective deployment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseClinical Trials as TopicHumansTreatment FailureAntibodies, MonoclonalDrug Development

Stichwörter der Autor:innen

Alzheimer's diseaseadaptive platform trialclinical trial failurepatient enrichmenttaxonomy

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • 2E Science, Robbio, Italy.
  • Department of Social Sciences, Miguel de Cervantes European University (UEMC), Valladolid, Spain.
  • Studio Minoretti, Oggiono, Italy.

ORCID-Profile: Enzo Emanuele, Piercarlo Minoretti

Zitieren

APA

Emanuele, E., & Minoretti, P. (2026). Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future. The FASEB Journal. https://doi.org/10.1096/fj.202601680rr

Vancouver

Emanuele E, Minoretti P. Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future. The FASEB Journal. 2026. doi:10.1096/fj.202601680rr

BibTeX
@article{Emanuele2026,
  author = {Emanuele, Enzo and Minoretti, Piercarlo},
  title = {Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future},
  journal = {The FASEB Journal},
  year = {2026},
  doi = {10.1096/fj.202601680rr}
}
Kostenlos starten →